In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sequenom Pharmaceuticals

Division of Sequenom Inc.
www.gemini-genomics.com

Latest From Sequenom Pharmaceuticals

Recent Public Biotech Acquisitions

While biotechs selling services to Big Pharma appear to avoid the risks of product development, profitability has nevertheless proved much more elusive to these companies than originally expected, as demonstrated by their acquisition prices.
BioPharmaceutical Business Strategies

Can Two Toolkits Make a Sustainable Business?

Things went downhill for population genetics company Gemini Genomics PLC after its IPO in July 2000, the most successful public offering of a UK company that year. Less than twelve months after raising $97 million on Nasdaq (where it hoped for greater visibility than from a London listing, given the paucity of UK genomics companies), the company has been bought by the German-American Sequenom Inc., in an all-paper deal worth about $224 million . Taking into account Gemini's net assets of $81.4 million, this values its technology at less than $150 million, a far cry from the company's $450 million market capitalization at its IPO.
BioPharmaceutical Strategy

The Population Genetics Equation: Data + Product Focus = Funding

Given the ho-hum attitude investors have shown toward population genetics, Xenon Genetics' $45 million private placement is notable. Now that the dust has settled on two of the older companies in the field, deCode Genetics and Gemini Genomics, which went public in July 2000, it is clear that the market gives them little technology value. But Xenon believes it can differentiate itself by the breadth of its data, which come from 28 populations, and its product-oriented approach.
BioPharmaceutical Platform Technologies

European Biotech IPOs Go Global

European biotech IPOs, spurred by the emergence of new European high tech exchanges such as Germany's Neuer Markt and France's Nouveau Marche, reached something of a milestone last year: while there were considerably fewer biotech IPOs completed on these exchanges, for the first time, the average amount raised in these deals was higher than those completed on NASDAQ.
BioPharmaceutical Europe
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • Genomics-Proteomics
  • Pharmaceuticals
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Gemini Holdings PLC
  • GEMINI GENOMICS PLC
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • UK
  • Parent & Subsidiaries
  • Sequenom Inc.
  • Senior Management
  • Paul Kelly, MD, Pres. & CEO
    Tony Ratcliffe, CFO
    Patrick Kleyn, PhD, CSO
    Zahed Subhan , PhD, EVP, Bus. Dev.
  • Contact Info
  • Sequenom Pharmaceuticals
    Phone: (44) 1223 4353
    162 Science Park, Milton Rd.
    Cambridge, CB4 0GH
    UK
UsernamePublicRestriction

Register